An expanding role for antithrombotic therapy in cancer patients

被引:21
作者
Kakkar, AK [1 ]
机构
[1] Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Dept Surg Oncol & Technol, London W12 0NN, England
关键词
antithrombotic therapy; cancer patients; low-molecular-weight heparin (LMWH); survival; venous thromboembolism;
D O I
10.1016/S0305-7372(03)80006-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Thromboembolic disease has a negative impact on outcome in the cancer patient. Venous thromboembolism appears to be a more aggressive disease in patients with cancer who present with both a greater thrombus burden and more pronounced derangements of coagulation parameters than non-cancer patients with thrombosis. Retrospective analyses suggest that treatment of venous thromboembolism in cancer patients with low-molecular-weight heparin is associated with additional benefits in terms of their survival. The mechanism for this effect is unclear but may be attributable to a reduced incidence of recurrent thrombosis and fatal pulmonary embolism in those patients with underlying thrombosis. To investigate the potential of low-molecular-weight heparin to prolong survival in cancer patients without underlying thrombosis, a prospective trial (FAMOUS) has evaluated the effect of treatment with the low-molecular-weight heparin dalteparin for 1 year in terms of survival of patients with advanced cancer and no underlying thrombosis. (C) 2003 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:23 / 26
页数:4
相关论文
共 22 条
  • [1] Tissue factor expression and angiogenesis in human prostate carcinoma
    Abdulkadir, SA
    Carvalhal, GF
    Kaleem, Z
    Kisiel, W
    Humphrey, PA
    Catalona, WJ
    Milbrandt, J
    [J]. HUMAN PATHOLOGY, 2000, 31 (04) : 443 - 447
  • [2] Heparin and cancer revisited: Mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis
    Borsig, L
    Wong, R
    Feramisco, J
    Nadeau, DR
    Varki, NM
    Varki, A
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (06) : 3352 - 3357
  • [3] Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis.
    Breddin, HK
    Hach-Wunderle, V
    Nakov, R
    Kakkar, VV
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (09) : 626 - 631
  • [4] Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis - A meta-analysis of randomized, controlled trials
    Gould, MK
    Dembitzer, AD
    Doyle, RL
    Hastie, TJ
    Garber, AM
    [J]. ANNALS OF INTERNAL MEDICINE, 1999, 130 (10) : 800 - +
  • [5] LOWER MORTALITY IN CANCER-PATIENTS TREATED WITH LOW-MOLECULAR-WEIGHT VERSUS STANDARD HEPARIN
    GREEN, D
    HULL, RD
    BRANT, R
    PINEO, GF
    [J]. LANCET, 1992, 339 (8807) : 1476 - 1476
  • [6] Do heparins do more than just treat thrombosis?: The influence of heparins on cancer spread
    Hettiarachchi, RJK
    Smorenburg, SM
    Ginsberg, J
    Levine, M
    Prins, MH
    Büller, HR
    [J]. THROMBOSIS AND HAEMOSTASIS, 1999, 82 (02) : 947 - 952
  • [7] Kakkar AK, 2002, BLOOD, V100, p148A
  • [8] Kakkar AK, 2000, BLOOD, V96, p449A
  • [9] KAKKER A, 2001, THROMB HAEMOST
  • [10] Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy - Risk analysis using Medicare claims data
    Levitan, N
    Dowlati, A
    Remick, SC
    Tahsildar, HI
    Sivinski, LD
    Beyth, R
    Rimm, AA
    [J]. MEDICINE, 1999, 78 (05) : 285 - 291